Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?

Lipoprotein(a) looks, at the molecular level, like trouble for blood clotting. Its protein component is a near-twin of plasminogen, the molecule the body uses to dissolve clots — so for years the assumption was that Lp(a) drives disease partly by jamming clot breakdown. This review asks whether that tidy story is actually true.

In the test tube, the case looks strong. Lp(a) inhibits the breakdown of fibrin, interferes with plasminogen activation, binds a key anticoagulant protein, and nudges clots toward a denser, harder-to-dissolve structure. If those effects mattered in the body, Lp(a) should raise the risk of clots everywhere — including venous clots like deep-vein thrombosis, the “pure” clotting disorders.

It doesn’t. The decisive evidence comes from genetics: studies using inherited LPA variants find a strong link between Lp(a) and arterial disease but no association with venous thrombosis. That dissociation is the review’s pivot. It implies Lp(a)’s danger is bound up with atherosclerosis in the artery wall, not with clotting per se — and that the plasminogen resemblance may be more evolutionary coincidence than active mechanism.

The reframing is mechanistic rather than bedside, and the authors are careful about its limits: venous-thrombosis studies could be underpowered, and children, intriguingly, do show an Lp(a)–clot association.

We rate the evidence high for a review of this kind — a fair, deeply referenced synthesis of biochemistry, cell biology, and human genetics, with the Mendelian data doing real argumentative work. Its clinical significance is high too, because the conclusion shapes strategy: if Lp(a) harms through atherosclerosis and inflammation rather than clotting, then therapy should target the particle and its inflammatory cargo — which is exactly where the field has since gone.